Use of anticoagulants in the production of recombinant proteins in the milk of transgenic animals
US9546381B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Mar 11, 2011 |
| Grant date | Jan 17, 2017 |
| Priority date | — |
| Expiry date | Jul 24, 2032 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA01K2267/01
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to the production of recombinant human fibrinogen (rhFib) in the milk of transgenic mammalian animals. This production and subsequent purification process is generally hampered by the occurrence of so-called ‘clots’ and ‘flakes’ in the milk which, in severe cases, may prevent the cow from being milked at all, resulting in a halt of lactation. These clots and flakes occur because of the expression of the fibrinogen protein, which is a factor that is normally involved in blood clotting. The invention relates to solving this milk clotting problem by treating the (lactating) animals with anticoagulants such as coumarins. A preferred anticoagulant that is used in the methods of the present invention is warfarin.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.